Literature DB >> 17852834

Fecal calprotectin: assessment of a rapid test.

T A Vestergaard1, S L Nielsen, J F Dahlerup, N Hornung.   

Abstract

BACKGROUND: Calprotectin, a protein found mainly in neutrophil granulocytes, is used as an inflammatory marker, while the fecal concentration of the protein is used to detect gastrointestinal (GI) inflammation.
MATERIAL AND METHODS: Fecal calprotectin in 100 stool samples was measured by the ELISA method and by a new rapid test. Eighty-two patients had fecal calprotectin measured for clinical reasons and delivered 95 stool samples. The rest were delivered by healthy volunteers.
RESULTS: The association between the two tests was statistically significant (p<0.0001, chi(2) test). With calprotectin values <15 microg/g, the sensitivity and specificity of the new rapid test was 96 % (95 % confidence interval (CI), 87-100 %) and 70 % (CI, 55-83 %), respectively, with a negative predictive value of 94 % (CI, 81-99 %). With values >15 microg/g, the rapid test was less accurate, thus rendering results in this range difficult to interpret.
CONCLUSIONS: The new rapid test is useful as a screening test for excluding GI inflammation when the cut-off of 15 microg/g is used. With fecal calprotectin concentrations >15 microg/g, the rapid test should be supplemented by quantitative measurement.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17852834     DOI: 10.1080/00365510701576198

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  10 in total

1.  Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; GianMarco Giorgetti; Giovanni Brandimarte
Journal:  Dig Dis Sci       Date:  2014-12-02       Impact factor: 3.199

2.  Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease.

Authors:  Delphine Labaere; Annick Smismans; August Van Olmen; Paul Christiaens; Geert D'Haens; Veerle Moons; Pieter-Jan Cuyle; Johan Frans; Peter Bossuyt
Journal:  United European Gastroenterol J       Date:  2014-02       Impact factor: 4.623

3.  Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.

Authors:  Anna-Maija Puolanne; Kaija-Leena Kolho; Henrik Alfthan; Ari Ristimäki; Harri Mustonen; Martti Färkkilä
Journal:  Dig Dis Sci       Date:  2017-09-25       Impact factor: 3.199

4.  Increased faecal calprotectin predicts recurrence of colonic diverticulitis.

Authors:  Antonio Tursi; Walter Elisei; Marcello Picchio; Giovanni Brandimarte
Journal:  Int J Colorectal Dis       Date:  2014-05-07       Impact factor: 2.571

Review 5.  Biomarkers as potential treatment targets in inflammatory bowel disease: A systematic review.

Authors:  Travis Murdoch; Sarah O'Donnell; Mark S Silverberg; Remo Panaccione
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

Review 6.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

7.  Faecal calprotectin in colonic diverticular disease: a case-control study.

Authors:  Antonio Tursi; Giovanni Brandimarte; Walter Elisei; Gian Marco Giorgetti; Cosimo Damiano Inchingolo; Fabio Aiello
Journal:  Int J Colorectal Dis       Date:  2008-10-22       Impact factor: 2.571

8.  Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome.

Authors:  Ulrike von Arnim; Thomas Wex; Christine Ganzert; Christian Schulz; Peter Malfertheiner
Journal:  Clin Exp Gastroenterol       Date:  2016-04-21

Review 9.  The Role of Laboratory Tests in Crohn's Disease.

Authors:  Maria Cappello; Gaetano Cristian Morreale
Journal:  Clin Med Insights Gastroenterol       Date:  2016-08-18

10.  Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution.

Authors:  David Díaz-Jiménez; Marjorie De la Fuente; Karen Dubois-Camacho; Glauben Landskron; Janitza Fuentes; Tamara Pérez; María Julieta González; Daniela Simian; Marcela A Hermoso; Rodrigo Quera
Journal:  BMC Gastroenterol       Date:  2016-08-26       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.